# Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

> **NCT03299088** · PHASE1 · COMPLETED · sponsor: **Jonathan Riess** · enrollment: 15 (actual)

## Conditions studied

- KRAS Gene Mutation
- Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
- Recurrent Non-Squamous Non-Small Cell Lung Carcinoma
- Stage IV Non-Small Cell Lung Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT03299088
- **Lead sponsor:** Jonathan Riess
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-26
- **Primary completion:** 2021-01-28
- **Final completion:** 2024-06-25
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-05-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03299088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03299088, "Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03299088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*